Drug intelligence / Profile preview

RU 58642

Development stage: Phase 2
Lead developer: Hoechst
Modality: Small Molecules
Administration: Oral

Overview

RU 58642 is a non-steroidal androgen receptor antagonist that was developed by Sanofi (formerly Roussel-Uclaf and Aventis) for the treatment of prostate cancer. As an arylacenamide derivative, it functions by competitively inhibiting the binding of androgens, such as testosterone and dihydrotestosterone, to the androgen receptor, thereby blocking the signaling pathways that drive the growth of prostate cancer cells. The drug was specifically investigated in Phase II clinical trials for patients with non-metastatic androgen-independent (castration-resistant) prostate cancer, where it was evaluated at doses of 75 mg and 125 mg. However, development of RU 58642 was ultimately discontinued.

Other names: arylacenamide

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on RU 58642.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RU 58642.

Explore the full profile